Acarix publishes a supplement to the prospectus

The board of directors of Acarix AB ("Acarix" or the "Company") has prepared a supplement to the
prospectus regarding invitation to acquire shares in the approved preferential rights issue in Acarix
which was approved by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) on 20
August, 2020 and published by the Company on the same date. The supplementary prospectus has
been prepared due to the information in the Company's press release on 2 September 2020
regarding the transfer of subscription rights from the two largest shareholders and the Company's
press release earlier today regarding the German Ministry of Health's statement that
phonocardiography for ruling out coronary artery disease has potential for general use in Germany


.Acarix_PR_prospectus_supplement (003)

Acarix_PM_offentliggörande_av_tilläggsprospekt (003)


About Acarix
Acarix was establish in 2009 and is listed on Nasdaq First North Growth Market. Acarix's CADScor@System uses an advanced sensor placed on the skin above the heart to listen to the sounds of cardiac contraction movement and turbulent flow. It has been designed to be an all-in-on system in the sense that the heart signal will be recorded, processed, and displayed as a patient specific score, the CAD-score, on the device screen.